Several equities analysts have recently issued reports on the stock. Evercore ISI raised their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an "outperform" rating in a research note on Monday, September 22nd. Morgan Stanley raised their target price on AbbVie from $250.00 to $255.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Bank of America lifted their target price on AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. BMO Capital Markets increased their price target on AbbVie from $215.00 to $240.00 and gave the company an "outperform" rating in a research note on Friday, September 12th. Finally, Cantor Fitzgerald lifted their price objective on AbbVie from $215.00 to $245.00 and gave the stock an "overweight" rating in a research note on Monday, September 15th.